Faron Pharma Share News (FARN)
FARN Share
FARN Share
FARN Share
FARN Share
FARN
FARN Share
FARN Level 2
FARN Live
FARN Broker
FARN Directors
FARN Financial
FARN
FARN Short
FARN
Last checked at -
(Sharecast News) - Clinical stage biopharmaceutical company Faron Pharmaceuticals announced on Friday that the first patient has successfully been dosed in the phase I/II MATINS study of Clevegen, its wholly-owned novel precision cancer immunotherapy drug.
Read more
LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Wednesday.----------FTSE 100 - up 2.7%. Japan's Takeda Pharmaceutical
Read more(Sharecast News) - Clinical stage biopharmaceutical company Faron Pharmaceuticals has identified, by genetic testing, an "optimal subgroup" of acute respiratory distress syndrome (ARDS) patients for Traumakine treatment who showed a substantial reduction in mortality during the INTEREST trial, it announced on Wednesday.
Read moreLONDON (Alliance News) - Faron Pharmaceuticals Ltd shares jumped on Wednesday as the company said it identified an "optimal" subgroup of patients, with a certain genetic mutation, to be
Read moreLONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Monday.----------FTSE 100 - up 8.9%, Evraz, up 7.8%, up
Read more(Sharecast News) - Clinical stage biopharmaceutical company Faron Pharmaceuticals announced on Monday that its clinical trial application to conduct a Phase I/II study with 'Clevegen', its wholly-owned novel precision cancer immunotherapy drug in development for the treatment of selected metastatic or inoperable tumours, has been approved by the Finnish Medicines Agency (FIMEA).
Read moreLONDON (Alliance News) - Faron Pharmaceuticals Oy on Tuesday said VP Drug Development Chief Medical Officer Matti Karvonen acquired shares in the biopharmaceutical company.In a transaction
Read moreLONDON (Alliance News) - Faron Pharmaceuticals Ltd said Monday that it has found evidence suggesting that corticosteroids used in parallel to its Traumakine treatment had a significant effect on a
Read moreLONDON (Alliance News) - Faron Pharmaceuticals Oy said Monday it has filed a clinical trial application for its cancer immunotherapy drug Clevegen.Clevegen, an anti-Clever-1 antibody, the a
Read moreLONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Thursday.----------FTSE 100 - WINNERS----------Royal Bank a
Read moreLONDON (Alliance News) - Shares in Faron Pharmaceuticals Ltd dropped on Thursday after the company said its loss for the first half of its financial year increased on higher research were trading
Read more(Sharecast News) - Faron Pharmaceuticals' operating loss doubled in the first half of its trading year following the group's disappointing trial on its Traumakine treatment.
Read moreLONDON (Alliance News) - Faron Pharmaceuticals Ltd said Wednesday that new data from its cell surface receptor Clever-1 showed B cell response control and humoral antibody production.The by
Read moreFriday 7 September Secure Income REITHalf Year Results Ashmore GroupFull Year Year
Read moreLONDON (Alliance News) - Faron Pharmaceuticals Oy said on Thursday several directors purchased shares over the course of three days from Tuesday to Thursday.On Tuesday, Non-Executive Matti
Read more
Last checked at